NASDAQ:SGTX Sigilon Therapeutics (SGTX) Stock Price, News & Analysis → Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad) Free SGTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$22.09▼$23.1050-Day Range$20.92▼$23.0652-Week Range$3.77▼$28.00Volume83,600 shsAverage Volume62,902 shsMarket Capitalization$56.40 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 Stock AnalysisStock Analysis Get Sigilon Therapeutics alerts: Email Address Ad Sasco Gold LLCDon’t make this retirement mistakeIf you have over $100,000 in your 401K or IRA… Then listen closely… Your money is rotting away, and you might not even realize it.Reserve your seat here. About Sigilon Therapeutics Stock (NASDAQ:SGTX)Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More Ad Sasco Gold LLCDon’t make this retirement mistakeIf you have over $100,000 in your 401K or IRA… Then listen closely… Your money is rotting away, and you might not even realize it.Reserve your seat here. SGTX Stock News HeadlinesMay 1, 2024 | benzinga.comLilly & Co Eli's Net WorthApril 14, 2024 | seekingalpha.comMCRB Seres Therapeutics, Inc.October 22, 2023 | wsj.comBeam Therapeutics Inc.August 14, 2023 | markets.businessinsider.comEli Lilly Concludes Acquisition Of Sigilon TherapeuticsAugust 14, 2023 | finance.yahoo.comLilly Completes Acquisition of Sigilon TherapeuticsAugust 1, 2023 | finance.yahoo.comSGTX - Sigilon Therapeutics, Inc.July 31, 2023 | msn.comInside Eli Lilly's Strategic Investment In Sigilon: An Opportunity OverlookedJuly 21, 2023 | businesswire.comSIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon ...July 18, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WMC, SGTX, AJX, IMNMJuly 6, 2023 | msn.comCanaccord Genuity Maintains Sigilon Therapeutics (SGTX) Buy RecommendationJuly 6, 2023 | msn.comSigilon Therapeutics (SGTX) Price Target Decreased by 6.27% to 48.28July 3, 2023 | msn.com5 big deal reports: Overstock snags Bed Bath & Beyond IP; Visa pays $1B for PismoJune 29, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Sigilon Therapeutics, Inc. BuyoutJune 29, 2023 | finance.yahoo.comModerna Billionaire Set to Score 3,000% Gain on Tiny BiotechJune 29, 2023 | finanznachrichten.deEli Lilly and Company: Lilly to Acquire Sigilon TherapeuticsJune 29, 2023 | msn.comHealth Care Company Eli Lilly Announces Acquisition of Sigilon TherapeuticsJune 29, 2023 | bizjournals.comSigilon stock up 500% on Lilly acquisition newsJune 29, 2023 | finance.yahoo.comSigilon Therapeutics Shares Are Shooting Higher Today - What's Going OnJune 29, 2023 | msn.comSigilon stock skyrockets 650% on buyout deal with Eli LillyJune 29, 2023 | markets.businessinsider.comEli Lilly To Acquire Sigilon TherapeuticsJune 29, 2023 | msn.comWhy Is Sigilon Therapeutics (SGTX) Stock Up 691% Today?June 29, 2023 | technews.tmcnet.comSGTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sigilon Therapeutics, Inc. Is Fair to ShareholdersJune 29, 2023 | finance.yahoo.comLilly to Acquire Sigilon TherapeuticsJune 29, 2023 | finance.yahoo.comEli Lilly to buy Sigilon Therapeutics to expand diabetes treatmentsMay 26, 2023 | markets.businessinsider.comMorgan Stanley Sticks to Their Hold Rating for Sigilon Therapeutics (SGTX)See More Headlines Receive SGTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sigilon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today6/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SGTX CUSIPN/A CIK1821323 Websigilon.com Phone617-336-7540FaxN/AEmployees62Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$21.00 Low Stock Price Target$21.00 Potential Upside/Downside-6.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($12.2328) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-43,560,000.00 Net Margins-171.29% Pretax Margin-171.29% Return on Equity-83.07% Return on Assets-38.17% Debt Debt-to-Equity RatioN/A Current Ratio1.78 Quick Ratio1.78 Sales & Book Value Annual Sales$12.94 million Price / Sales4.36 Cash FlowN/A Price / Cash FlowN/A Book Value$15.68 per share Price / Book1.43Miscellaneous Outstanding Shares2,510,000Free Float2,351,000Market Cap$56.40 million OptionableNot Optionable Beta4.12 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Rogerio Vivaldi Coelho M.B.A. (Age 59)M.D., MBA, Pres, CEO & Director Comp: $924.67kMr. Philip Ashton-Rickardt Ph.D. (Age 59)Chief Scientific Officer Comp: $614.08kDr. Robert S. Langer Jr. (Age 74)Ph.D., Sc.D., SCD, Co-Founder & Member of Scientific Advisory Board Dr. Daniel G. Anderson Ph.D. (Age 53)Co-Founder & Member of Scientific Advisory Board Dr. Omid Veiseh Ph.D.Co-FounderDr. José Oberholzer M.D.Co-FounderDr. Arturo Vegas Ph.D.Co-FounderMr. Josias Fantato De Pontes M.B.A. (Age 56)CFO, Principal Accounting Officer & Treasurer Mr. Bernd Kullmann M.B.A.Sr. VP and Head of Operations & Project ManagementMr. Matthew P. Kowalsky J.D. (Age 50)Chief of Staff, Chief Legal and Admin. Officer & Sec. More ExecutivesKey Competitors2seventy bioNASDAQ:TSVTOmerosNASDAQ:OMERConduit PharmaceuticalsNASDAQ:CDT23andMeNASDAQ:MEPyxis OncologyNASDAQ:PYXSView All CompetitorsInsidersLilly & Co EliBought 1,718,493 shares on 8/11/2023Total: $25.64 M ($14.92/share) SGTX Stock Analysis - Frequently Asked Questions Should I buy or sell Sigilon Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sigilon Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SGTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGTX, but not buy additional shares or sell existing shares. View SGTX analyst ratings or view top-rated stocks. What is Sigilon Therapeutics' stock price target for 2024? 2 equities research analysts have issued 12 month price objectives for Sigilon Therapeutics' shares. Their SGTX share price targets range from $21.00 to $21.00. On average, they predict the company's share price to reach $21.00 in the next year. This suggests that the stock has a possible downside of 6.5%. View analysts price targets for SGTX or view top-rated stocks among Wall Street analysts. How were Sigilon Therapeutics' earnings last quarter? Sigilon Therapeutics, Inc. (NASDAQ:SGTX) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($8.19) earnings per share for the quarter, topping the consensus estimate of ($8.58) by $0.39. The firm earned $1.95 million during the quarter, compared to analysts' expectations of $3.20 million. Sigilon Therapeutics had a negative trailing twelve-month return on equity of 83.07% and a negative net margin of 171.29%. When did Sigilon Therapeutics' stock split? Shares of Sigilon Therapeutics reverse split on Tuesday, May 23rd 2023. The 1-13 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. When did Sigilon Therapeutics IPO? Sigilon Therapeutics (SGTX) raised $101 million in an IPO on Friday, December 4th 2020. The company issued 5,600,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, Jefferies, Barclays and Canaccord Genuity acted as the underwriters for the IPO. This page (NASDAQ:SGTX) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredDON’T buy gold until you read thisIf you're an American who understands that your money is rotting away as you read this email… Then this is ...Sasco Gold LLC | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sigilon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sigilon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.